Today many new drug candidates have a low aqueous solubility. This causes several problems. For example, in oral administration it often results in low and variable bioavailability. For intravenous administration it is difficult to deliver the intended dose in a suitable volume. When it comes to addressing these issues there are two widely adopted approaches, the solid state properties of the drug substance can be modified in order to increase solubility or the drug product can be modified in order to limit the effects of the low solubility.